Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
The Finnish government approves an annual drug budget that is in line with its drug strategy and action plan. Annual estimates of expenditures are also provided and include both labelled and unlabelled expenditures. The most recent available data on public expenditure in Finland are for 2013. Estimates for more recent years are expected in 2018.
In 2013, total drug-related expenditure represented 0.2 % of gross domestic product, which was approximately EUR 412 000. Of this, the majority was spent on public order and safety, and the remaining budget on social protection and healthcare.
In 2013, total drug-related public expenditure in Finland remained broadly unchanged in real terms (it increased by 1 %) compared with 2012; however, it increased by 2.4 % in nominal terms.